Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7321-7330 Newer>

The Motley Fool April 11, 2011 Brian Orelli	A Double Dose of Trouble for Big Pharma? Pfizer's Sutent and Novartis's Afinitor head in front of an FDA advisory panel.
The Motley Fool April 11, 2011 Brian Orelli	Clinical Trial Fail? Forget About It. A failure of Medivation and Pfizer's dimebon was expected.
The Motley Fool April 11, 2011 Jim Mueller	A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too.
The Motley Fool April 9, 2011 Luke Timmerman	Evolve or Die: 4 Ways Med-Device Companies Can Survive Versant's Beckie Robertson speaks her mind.
The Motley Fool April 8, 2011 Brian Orelli	ImmunoGen's Hot Start ImmunoGen scores some positive data, but were investors expecting less?
The Motley Fool April 8, 2011 Brian Orelli	A Shutdown of Binary Events? A government shutdown will likely stop FDA approvals.
The Motley Fool April 8, 2011 Yael Grauer	Medtronic to Combine Cardiac and Vascular Sales Forces What does Medtronic's new sales strategy mean?
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
The Motley Fool April 7, 2011 Brian Orelli	When Zombies Attack, Investors Win Novartis is hoping that Prexige has as much success coming back from the dead as Tysabri has.
The Motley Fool April 7, 2011 Brian Orelli	Restless No Longer XenoPort and Glaxo get a delayed FDA approval.
<Older 7321-7330 Newer> Return to current articles.